House committee approves requiring state employee plans to cover FDA‑approved Alzheimer’s treatments

Representative Julie Mayberry on Wednesday asked the Insurance & Commerce Committee to approve House Bill 1055 so state employees and public‑school employees would have the same access to FDA‑approved Alzheimer’s treatments now available through Medicare, Medicaid and the Veterans Health Administration.

The bill passed the committee by voice vote; a formal roll‑call tally was not recorded in the hearing record. Representative Mayberry sponsored the measure and closed for the bill after a full hearing with medical experts, patient families and Employee Benefits Division (EBD) staff.

Supporters told the committee the bill is narrowly targeted to early‑stage patients who meet strict clinical criteria and registry requirements. David Cook, director of government affairs for the Alzheimer’s Association, said the decision to treat should be made by clinicians rather than benefit administrators and that delaying access can increase costly late‑stage care. "This ensures that state employees have the same level of access that Arkansans who participate in the state Medicaid program and those veterans who can access these treatments," Cook said.

Neurologist Morgan Sauer described the treatments as targeting underlying biology rather than behavior and emphasized the narrow clinical window for use. "These medications are not for behavioral modification…they are only used in people who have very early Alzheimer’s disease or have what we call mild cognitive impairment," Dr. Sauer said, adding that careful testing and monitoring are required and that many Arkansans must travel out of state for some specialized imaging.

Family witnesses gave the committee personal accounts of being denied access through private assistance or having to pay out of pocket. Lori Case Melton, whose husband was diagnosed with early‑onset Alzheimer’s, said the couple was denied drug company assistance because their household income exceeded the company’s threshold. "We literally would have had to get divorced in order for him to get his treatment," Melton testified.

EBD Director Grant Wallace cautioned lawmakers that the division has a fiduciary duty to manage plan costs and that the bill would limit the agency’s ability to perform utilization management. Wallace said his office projected the legislation carries a price tag in the $2 million to $4 million range under a worst‑case scenario and noted that the drugs themselves plus required monitoring can drive higher medical spending. "This legislation does have a high price tag," Wallace said. He also said the bill would require EBD to cover FDA‑approved drugs as they come to market and would constrain the division’s ability to apply stricter utilization controls than the FDA label.

Supporters disputed the high fiscal estimates and said the population of state‑plan participants who would qualify is small. Cook and the Alzheimer’s Association used prevalence estimates to argue that, conservatively, only a few dozen state‑plan members would be eligible for treatment: based on age cohorts and published rates, the association estimated roughly 29 people in the relevant pool might qualify. Witnesses also gave varying per‑patient cost estimates: EBD cited per‑patient medication and monitoring scenarios that were summarized in the fiscal analysis; patient witnesses and advocates reported drug manufacturers’ cash prices and assistance thresholds in testimony (a cited negotiated cash price was about $5,000 per month in one account).

Committee members pressed both sides on guardrails: which clinicians may prescribe the drugs, whether specialized imaging or cerebrospinal fluid testing would be required, how registries and REMS‑style monitoring would be enforced, and whether prior authorization would remain available. Dr. Sauer and Cook said most payers follow Medicare’s criteria and require specialty clinicians (neurologists, geriatricians, behavioral neurologists), disease‑specific testing for amyloid, and registration in national treatment registries. Mayberry pointed to language in the bill that allows EBD to follow the FDA label and argued the bill does not prohibit reasonable prior authorization; Wallace responded that the legislation limits how restrictive the division can be compared with the FDA label and constrains the usual deliberative review process EBD follows for new‑to‑market therapies.

The committee heard repeated testimony that the treatments are not cures but can slow progression when started early and that close monitoring for adverse effects — including repeated MRI surveillance for potential brain bleeding — is required. Supporters framed access as an equity issue for state employees and school employees who currently have less access through EBD than people covered by Medicare, Medicaid or the VA. EBD cautioned that federal rebate rules and other program differences mean cost comparisons across programs are not one‑to‑one.

Action: committee members moved and approved passage of House Bill 1055. The committee’s voice vote was announced on the record; specific vote tallies were not provided.

The bill now moves to further House consideration where lawmakers will weigh EBD’s fiduciary concerns against advocates’ arguments about clinical access and patient benefit.